bionlp-st-ge-2016-spacy-parsed Home  

PMC:1064895 / 20649-21991 JSONTXT 23 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T16414 0-2 TO denotes To
T16415 3-14 VB denotes investigate
T16416 15-22 RB denotes further
T16417 23-26 DT denotes the
T16418 27-40 JJ denotes intracellular
T16419 41-50 VBG denotes signaling
T16420 51-58 NN denotes pathway
T16421 59-68 VBN denotes activated
T16422 69-71 IN denotes by
T16423 72-80 JJ denotes anti-CD3
T16424 81-85 CC denotes plus
T16425 86-95 JJ denotes anti-CD28
T16426 95-96 , denotes ,
T16427 97-109 JJ denotes concanavalin
T16428 110-111 DT denotes A
T16429 111-112 , denotes ,
T16430 113-116 NNP denotes PHA
T16431 117-120 CC denotes and
T16432 121-126 NNP denotes IL-15
T16433 126-127 , denotes ,
T16434 128-131 CC denotes and
T16435 132-143 JJ denotes responsible
T16436 144-147 IN denotes for
T16437 148-156 VBG denotes inducing
T16438 157-162 NNP denotes IL-17
T16439 163-173 NN denotes expression
T16440 173-174 , denotes ,
T16441 175-177 PRP denotes we
T16442 178-187 VBD denotes performed
T16443 188-190 DT denotes an
T16444 191-206 JJ denotes electrophoretic
T16445 207-221 NN denotes mobility-shift
T16446 222-227 NN denotes assay
T16447 228-229 -LRB- denotes (
T16448 229-233 NNP denotes EMSA
T16449 233-234 -RRB- denotes )
T16450 235-237 IN denotes of
T16451 238-243 NN denotes NF-κB
T16452 244-255 NN denotes recognition
T16453 256-261 NNS denotes sites
T16454 262-264 IN denotes in
T16455 265-268 DT denotes the
T16456 269-278 NNS denotes promoters
T16457 279-281 IN denotes of
T16458 282-287 NNP denotes IL-17
T16459 287-288 . denotes .
T16460 289-291 IN denotes As
T16461 292-297 VBN denotes shown
T16462 298-300 IN denotes in
T16463 301-305 NNP denotes Fig.
T16464 306-308 CD denotes 7a
T16465 308-309 , denotes ,
T16466 310-317 JJ denotes nuclear
T16467 318-326 NNS denotes extracts
T16468 327-331 IN denotes from
T16469 332-334 NNP denotes RA
T16470 335-339 NNP denotes PBMC
T16471 340-350 VBD denotes stimulated
T16472 351-355 IN denotes with
T16473 356-364 JJ denotes anti-CD3
T16474 365-369 CC denotes plus
T16475 370-379 JJ denotes anti-CD28
T16476 380-381 -LRB- denotes (
T16477 381-385 NN denotes lane
T16478 386-387 CD denotes 2
T16479 387-388 -RRB- denotes )
T16480 389-401 VBD denotes demonstrated
T16481 402-411 VBN denotes increased
T16482 412-419 JJ denotes binding
T16483 420-422 IN denotes of
T16484 423-428 NN denotes NF-κB
T16485 429-431 TO denotes to
T16486 432-437 NNP denotes IL-17
T16487 438-447 NNS denotes promoters
T16488 448-450 IN denotes in
T16489 451-461 NN denotes comparison
T16490 462-466 IN denotes with
T16491 467-471 DT denotes that
T16492 472-474 IN denotes of
T16493 475-483 NNS denotes controls
T16494 484-485 -LRB- denotes (
T16495 485-489 NN denotes lane
T16496 490-491 CD denotes 1
T16497 491-492 -RRB- denotes )
T16498 492-493 . denotes .
T16499 494-495 DT denotes A
T16500 496-506 NN denotes supershift
T16501 507-512 NN denotes assay
T16502 513-525 VBD denotes demonstrated
T16503 526-533 VBN denotes shifted
T16504 534-539 NNS denotes bands
T16505 540-542 IN denotes in
T16506 543-546 CD denotes p65
T16507 547-550 CC denotes and
T16508 551-554 CD denotes p50
T16509 555-556 -LRB- denotes (
T16510 556-561 NNS denotes lanes
T16511 562-563 CD denotes 3
T16512 564-567 CC denotes and
T16513 568-569 CD denotes 4
T16514 569-570 -RRB- denotes )
T16515 571-574 RB denotes not
T16516 575-577 IN denotes in
T16517 578-583 NNP denotes c-Rel
T16518 584-585 -LRB- denotes (
T16519 585-589 NN denotes lane
T16520 590-591 CD denotes 5
T16521 591-592 -RRB- denotes )
T16522 592-593 . denotes .
T16523 594-596 IN denotes In
T16524 597-603 JJ denotes normal
T16525 604-608 NNP denotes PBMC
T16526 609-612 DT denotes the
T16527 613-617 JJ denotes same
T16528 618-625 NN denotes pattern
T16529 626-629 VBD denotes was
T16530 630-638 VBN denotes observed
T16531 638-639 , denotes ,
T16532 640-643 CC denotes but
T16533 644-647 DT denotes the
T16534 648-654 NN denotes degree
T16535 655-657 IN denotes of
T16536 658-663 JJ denotes NF-κB
T16537 664-674 NN denotes activation
T16538 675-677 IN denotes by
T16539 678-686 JJ denotes anti-CD3
T16540 687-691 CC denotes plus
T16541 692-701 JJ denotes anti-CD28
T16542 702-705 VBD denotes was
T16543 706-710 JJR denotes less
T16544 711-718 JJ denotes intense
T16545 719-723 IN denotes than
T16546 724-728 DT denotes that
T16547 729-731 IN denotes in
T16548 732-734 NNP denotes RA
T16549 735-739 NNP denotes PBMC
T16550 740-741 -LRB- denotes (
T16551 741-745 NNP denotes Fig.
T16552 746-748 CD denotes 7b
T16553 748-749 -RRB- denotes )
T16554 749-750 . denotes .
T16555 751-753 TO denotes To
T16556 754-761 VB denotes confirm
T16557 762-765 DT denotes the
T16558 766-770 NN denotes link
T16559 771-778 IN denotes between
T16560 779-783 JJ denotes PI3K
T16561 784-792 NN denotes activity
T16562 793-796 CC denotes and
T16563 797-802 NN denotes NF-κB
T16564 802-803 , denotes ,
T16565 804-806 PRP denotes we
T16566 807-816 VBD denotes performed
T16567 817-821 NNP denotes EMSA
T16568 822-824 TO denotes to
T16569 825-834 VB denotes determine
T16570 835-838 DT denotes the
T16571 839-844 JJ denotes NF-κB
T16572 845-852 JJ denotes binding
T16573 853-861 NN denotes activity
T16574 862-867 IN denotes after
T16575 868-877 NN denotes treatment
T16576 878-882 IN denotes with
T16577 883-887 DT denotes both
T16578 888-896 CD denotes LY294002
T16579 897-900 CC denotes and
T16580 901-905 NNP denotes PDTC
T16581 905-906 . denotes .
T16582 907-911 DT denotes Both
T16583 912-918 NNS denotes agents
T16584 919-924 NN denotes block
T16585 925-930 NNP denotes NF-κB
T16586 931-942 JJ denotes DNA-binding
T16587 943-951 NN denotes activity
T16588 952-954 IN denotes in
T16589 955-958 DT denotes the
T16590 959-964 NNP denotes IL-17
T16591 965-973 NN denotes promoter
T16592 974-975 -LRB- denotes (
T16593 975-979 NNP denotes Fig.
T16594 980-982 CD denotes 7c
T16595 982-983 -RRB- denotes )
T16596 983-984 . denotes .
T16597 985-992 JJ denotes Western
T16598 993-1001 VBG denotes blotting
T16599 1002-1005 IN denotes for
T16600 1006-1011 JJ denotes IκB-α
T16601 1012-1018 VBD denotes showed
T16602 1019-1029 NN denotes inhibition
T16603 1030-1032 IN denotes of
T16604 1033-1044 NN denotes degradation
T16605 1045-1047 IN denotes of
T16606 1048-1053 JJ denotes IκB-α
T16607 1054-1056 IN denotes by
T16608 1057-1065 NNP denotes LY294002
T16609 1066-1069 CC denotes and
T16610 1070-1074 NNP denotes PDTC
T16611 1075-1077 IN denotes at
T16612 1078-1081 DT denotes the
T16613 1082-1086 JJ denotes same
T16614 1087-1091 NN denotes time
T16615 1092-1093 -LRB- denotes (
T16616 1093-1097 NNP denotes Fig.
T16617 1098-1100 CD denotes 7c
T16618 1100-1101 -RRB- denotes )
T16619 1101-1102 . denotes .
T16620 1103-1105 IN denotes In
T16621 1106-1114 NN denotes contrast
T16622 1114-1115 , denotes ,
T16623 1116-1119 DT denotes the
T16624 1120-1124 NNP denotes AP-1
T16625 1125-1132 NN denotes pathway
T16626 1133-1136 VBD denotes was
T16627 1137-1140 RB denotes not
T16628 1141-1150 VBN denotes activated
T16629 1151-1153 IN denotes by
T16630 1154-1165 NN denotes stimulation
T16631 1166-1170 IN denotes with
T16632 1171-1179 JJ denotes anti-CD3
T16633 1180-1184 CC denotes plus
T16634 1185-1194 JJ denotes anti-CD28
T16635 1195-1196 -LRB- denotes (
T16636 1196-1200 NNS denotes data
T16637 1201-1204 RB denotes not
T16638 1205-1210 VBN denotes shown
T16639 1210-1211 -RRB- denotes )
T16640 1211-1212 , denotes ,
T16641 1213-1226 VBG denotes demonstrating
T16642 1227-1231 IN denotes that
T16643 1232-1237 NNP denotes NF-κB
T16644 1238-1240 VBZ denotes is
T16645 1241-1244 DT denotes the
T16646 1245-1249 JJ denotes main
T16647 1250-1263 JJ denotes intracellular
T16648 1264-1273 VBG denotes signaling
T16649 1274-1281 NN denotes pathway
T16650 1282-1284 IN denotes in
T16651 1285-1290 JJ denotes IL-17
T16652 1291-1301 NN denotes production
T16653 1302-1304 IN denotes by
T16654 1305-1314 VBN denotes activated
T16655 1315-1319 NNP denotes PBMC
T16656 1320-1324 IN denotes from
T16657 1325-1333 NNS denotes patients
T16658 1334-1338 IN denotes with
T16659 1339-1341 NNP denotes RA
T16660 1341-1342 . denotes .
R8904 T16414 T16415 aux To,investigate
R8905 T16415 T16442 advcl investigate,performed
R8906 T16416 T16415 advmod further,investigate
R8907 T16417 T16420 det the,pathway
R8908 T16418 T16420 amod intracellular,pathway
R8909 T16419 T16420 amod signaling,pathway
R8910 T16420 T16415 dobj pathway,investigate
R8911 T16421 T16420 acl activated,pathway
R8912 T16422 T16421 agent by,activated
R8913 T16423 T16430 amod anti-CD3,PHA
R8914 T16424 T16423 cc plus,anti-CD3
R8915 T16425 T16423 conj anti-CD28,anti-CD3
R8916 T16426 T16425 punct ",",anti-CD28
R8917 T16427 T16428 compound concanavalin,A
R8918 T16428 T16425 conj A,anti-CD28
R8919 T16429 T16428 punct ",",A
R8920 T16430 T16422 pobj PHA,by
R8921 T16431 T16430 cc and,PHA
R8922 T16432 T16430 conj IL-15,PHA
R8923 T16433 T16432 punct ",",IL-15
R8924 T16434 T16421 cc and,activated
R8925 T16435 T16421 conj responsible,activated
R8926 T16436 T16435 prep for,responsible
R8927 T16437 T16436 pcomp inducing,for
R8928 T16438 T16439 compound IL-17,expression
R8929 T16439 T16437 dobj expression,inducing
R8930 T16440 T16442 punct ",",performed
R8931 T16441 T16442 nsubj we,performed
R8932 T16442 T16442 ROOT performed,performed
R8933 T16443 T16446 det an,assay
R8934 T16444 T16446 amod electrophoretic,assay
R8935 T16445 T16446 compound mobility-shift,assay
R8936 T16446 T16442 dobj assay,performed
R8937 T16447 T16446 punct (,assay
R8938 T16448 T16446 appos EMSA,assay
R8939 T16449 T16446 punct ),assay
R8940 T16450 T16446 prep of,assay
R8941 T16451 T16453 compound NF-κB,sites
R8942 T16452 T16453 compound recognition,sites
R8943 T16453 T16450 pobj sites,of
R8944 T16454 T16453 prep in,sites
R8945 T16455 T16456 det the,promoters
R8946 T16456 T16454 pobj promoters,in
R8947 T16457 T16456 prep of,promoters
R8948 T16458 T16457 pobj IL-17,of
R8949 T16459 T16442 punct .,performed
R8950 T16460 T16461 mark As,shown
R8951 T16461 T16471 advcl shown,stimulated
R8952 T16462 T16461 prep in,shown
R8953 T16463 T16462 pobj Fig.,in
R8954 T16464 T16463 nummod 7a,Fig.
R8955 T16465 T16463 punct ",",Fig.
R8956 T16466 T16467 amod nuclear,extracts
R8957 T16467 T16471 nsubj extracts,stimulated
R8958 T16468 T16467 prep from,extracts
R8959 T16469 T16470 compound RA,PBMC
R8960 T16470 T16468 pobj PBMC,from
R8961 T16471 T16471 ROOT stimulated,stimulated
R8962 T16472 T16471 prep with,stimulated
R8963 T16473 T16472 pobj anti-CD3,with
R8964 T16474 T16473 cc plus,anti-CD3
R8965 T16475 T16473 conj anti-CD28,anti-CD3
R8966 T16476 T16477 punct (,lane
R8967 T16477 T16473 appos lane,anti-CD3
R8968 T16478 T16477 nummod 2,lane
R8969 T16479 T16471 punct ),stimulated
R8970 T16480 T16471 conj demonstrated,stimulated
R8971 T16481 T16482 amod increased,binding
R8972 T16482 T16480 dobj binding,demonstrated
R8973 T16483 T16482 prep of,binding
R8974 T16484 T16483 pobj NF-κB,of
R8975 T16485 T16484 prep to,NF-κB
R8976 T16486 T16487 compound IL-17,promoters
R8977 T16487 T16485 pobj promoters,to
R8978 T16488 T16480 prep in,demonstrated
R8979 T16489 T16488 pobj comparison,in
R8980 T16490 T16489 prep with,comparison
R8981 T16491 T16490 pobj that,with
R8982 T16492 T16491 prep of,that
R8983 T16493 T16492 pobj controls,of
R8984 T16494 T16495 punct (,lane
R8985 T16495 T16493 parataxis lane,controls
R8986 T16496 T16495 nummod 1,lane
R8987 T16497 T16495 punct ),lane
R8988 T16498 T16471 punct .,stimulated
R8989 T16499 T16501 det A,assay
R8990 T16500 T16501 compound supershift,assay
R8991 T16501 T16502 nsubj assay,demonstrated
R8992 T16502 T16502 ROOT demonstrated,demonstrated
R8993 T16503 T16504 amod shifted,bands
R8994 T16504 T16502 dobj bands,demonstrated
R8995 T16505 T16502 prep in,demonstrated
R8996 T16506 T16510 nummod p65,lanes
R8997 T16507 T16506 cc and,p65
R8998 T16508 T16506 conj p50,p65
R8999 T16509 T16510 punct (,lanes
R9000 T16510 T16505 pobj lanes,in
R9001 T16511 T16510 nummod 3,lanes
R9002 T16512 T16511 cc and,3
R9003 T16513 T16511 conj 4,3
R9004 T16514 T16511 punct ),3
R9005 T16515 T16510 neg not,lanes
R9006 T16516 T16510 prep in,lanes
R9007 T16517 T16516 pobj c-Rel,in
R9008 T16518 T16519 punct (,lane
R9009 T16519 T16517 appos lane,c-Rel
R9010 T16520 T16519 nummod 5,lane
R9011 T16521 T16519 punct ),lane
R9012 T16522 T16502 punct .,demonstrated
R9013 T16523 T16530 prep In,observed
R9014 T16524 T16523 pobj normal,In
R9015 T16525 T16530 nsubjpass PBMC,observed
R9016 T16526 T16528 det the,pattern
R9017 T16527 T16528 amod same,pattern
R9018 T16528 T16525 appos pattern,PBMC
R9019 T16529 T16530 auxpass was,observed
R9020 T16530 T16530 ROOT observed,observed
R9021 T16531 T16530 punct ",",observed
R9022 T16532 T16530 cc but,observed
R9023 T16533 T16534 det the,degree
R9024 T16534 T16542 nsubj degree,was
R9025 T16535 T16534 prep of,degree
R9026 T16536 T16537 amod NF-κB,activation
R9027 T16537 T16535 pobj activation,of
R9028 T16538 T16537 prep by,activation
R9029 T16539 T16542 nsubj anti-CD3,was
R9030 T16540 T16539 cc plus,anti-CD3
R9031 T16541 T16539 conj anti-CD28,anti-CD3
R9032 T16542 T16530 conj was,observed
R9033 T16543 T16544 advmod less,intense
R9034 T16544 T16542 acomp intense,was
R9035 T16545 T16544 prep than,intense
R9036 T16546 T16545 pobj that,than
R9037 T16547 T16546 prep in,that
R9038 T16548 T16549 compound RA,PBMC
R9039 T16549 T16547 pobj PBMC,in
R9040 T16550 T16549 punct (,PBMC
R9041 T16551 T16549 appos Fig.,PBMC
R9042 T16552 T16551 nummod 7b,Fig.
R9043 T16553 T16549 punct ),PBMC
R9044 T16554 T16542 punct .,was
R9045 T16555 T16556 aux To,confirm
R9046 T16556 T16566 advcl confirm,performed
R9047 T16557 T16558 det the,link
R9048 T16558 T16556 dobj link,confirm
R9049 T16559 T16558 prep between,link
R9050 T16560 T16561 amod PI3K,activity
R9051 T16561 T16559 pobj activity,between
R9052 T16562 T16561 cc and,activity
R9053 T16563 T16561 conj NF-κB,activity
R9054 T16564 T16566 punct ",",performed
R9055 T16565 T16566 nsubj we,performed
R9056 T16566 T16566 ROOT performed,performed
R9057 T16567 T16566 dobj EMSA,performed
R9058 T16568 T16569 aux to,determine
R9059 T16569 T16566 advcl determine,performed
R9060 T16570 T16573 det the,activity
R9061 T16571 T16573 amod NF-κB,activity
R9062 T16572 T16573 amod binding,activity
R9063 T16573 T16569 dobj activity,determine
R9064 T16574 T16569 prep after,determine
R9065 T16575 T16574 pobj treatment,after
R9066 T16576 T16575 prep with,treatment
R9067 T16577 T16578 det both,LY294002
R9068 T16578 T16576 pobj LY294002,with
R9069 T16579 T16578 cc and,LY294002
R9070 T16580 T16578 conj PDTC,LY294002
R9071 T16581 T16566 punct .,performed
R9072 T16582 T16583 preconj Both,agents
R9073 T16583 T16584 nsubj agents,block
R9074 T16584 T16584 ROOT block,block
R9075 T16585 T16587 nmod NF-κB,activity
R9076 T16586 T16587 amod DNA-binding,activity
R9077 T16587 T16584 dobj activity,block
R9078 T16588 T16587 prep in,activity
R9079 T16589 T16591 det the,promoter
R9080 T16590 T16591 compound IL-17,promoter
R9081 T16591 T16588 pobj promoter,in
R9082 T16592 T16584 punct (,block
R9083 T16593 T16584 npadvmod Fig.,block
R9084 T16594 T16593 nummod 7c,Fig.
R9085 T16595 T16584 punct ),block
R9086 T16596 T16584 punct .,block
R9087 T16597 T16598 amod Western,blotting
R9088 T16598 T16601 nsubj blotting,showed
R9089 T16599 T16598 prep for,blotting
R9090 T16600 T16601 nsubj IκB-α,showed
R9091 T16601 T16601 ROOT showed,showed
R9092 T16602 T16601 dobj inhibition,showed
R9093 T16603 T16602 prep of,inhibition
R9094 T16604 T16603 pobj degradation,of
R9095 T16605 T16604 prep of,degradation
R9096 T16606 T16605 pobj IκB-α,of
R9097 T16607 T16601 prep by,showed
R9098 T16608 T16607 pobj LY294002,by
R9099 T16609 T16608 cc and,LY294002
R9100 T16610 T16608 conj PDTC,LY294002
R9101 T16611 T16601 prep at,showed
R9102 T16612 T16614 det the,time
R9103 T16613 T16614 amod same,time
R9104 T16614 T16611 pobj time,at
R9105 T16615 T16601 punct (,showed
R9106 T16616 T16601 dobj Fig.,showed
R9107 T16617 T16616 nummod 7c,Fig.
R9108 T16618 T16616 punct ),Fig.
R9109 T16619 T16601 punct .,showed
R9110 T16620 T16628 prep In,activated
R9111 T16621 T16620 pobj contrast,In
R9112 T16622 T16628 punct ",",activated
R9113 T16623 T16625 det the,pathway
R9114 T16624 T16625 compound AP-1,pathway
R9115 T16625 T16628 nsubjpass pathway,activated
R9116 T16626 T16628 auxpass was,activated
R9117 T16627 T16628 neg not,activated
R9118 T16628 T16628 ROOT activated,activated
R9119 T16629 T16628 agent by,activated
R9120 T16630 T16629 pobj stimulation,by
R9121 T16631 T16628 prep with,activated
R9122 T16632 T16636 amod anti-CD3,data
R9123 T16633 T16632 cc plus,anti-CD3
R9124 T16634 T16632 conj anti-CD28,anti-CD3
R9125 T16635 T16636 punct (,data
R9126 T16636 T16631 pobj data,with
R9127 T16637 T16638 neg not,shown
R9128 T16638 T16636 acl shown,data
R9129 T16639 T16636 punct ),data
R9130 T16640 T16628 punct ",",activated
R9131 T16641 T16628 advcl demonstrating,activated
R9132 T16642 T16644 mark that,is
R9133 T16643 T16644 nsubj NF-κB,is
R9134 T16644 T16641 ccomp is,demonstrating
R9135 T16645 T16649 det the,pathway
R9136 T16646 T16649 amod main,pathway
R9137 T16647 T16649 amod intracellular,pathway
R9138 T16648 T16649 amod signaling,pathway
R9139 T16649 T16644 attr pathway,is
R9140 T16650 T16649 prep in,pathway
R9141 T16651 T16652 amod IL-17,production
R9142 T16652 T16650 pobj production,in
R9143 T16653 T16649 prep by,pathway
R9144 T16654 T16655 amod activated,PBMC
R9145 T16655 T16653 pobj PBMC,by
R9146 T16656 T16649 prep from,pathway
R9147 T16657 T16656 pobj patients,from
R9148 T16658 T16649 prep with,pathway
R9149 T16659 T16658 pobj RA,with
R9150 T16660 T16628 punct .,activated